PODN

Across TCGA pan-cancer cohorts, PODN Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PODN data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PODN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PODN expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, UCEC, and PRAD are the cancer types where PODN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.191	0.833	<.001	21	view →
UCEC	DFS	Median	II,III,IV	0.928	0.438	.027	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	All	0.218	0.676	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PODN–BRCA (OS)

Open the BRCA breakdown →